CTC-413 for Parkinson's Disease

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Chase Therapeutics Corporation

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests a combination of Pramipexole ER and Aprepitant in patients with idiopathic Parkinson's disease. Pramipexole ER helps reduce Parkinson's symptoms by mimicking dopamine, while Aprepitant prevents nausea to improve tolerance of the treatment. Pramipexole is used to treat Parkinson's disease and is effective in both early and advanced stages.

Eligibility Criteria

This trial is for men and women aged 40-80 with a diagnosis of idiopathic Parkinson's disease, who haven't been treated with CD/LD and are in the Hoehn & Yahr stages 2 to 3. Excluded are pregnant or nursing women, recent participants in other trials, those with significant heart issues or severe kidney/liver problems, allergies to study meds, or on certain drugs like Warfarin.

Inclusion Criteria

I am between 40 and 80 years old.

I have been diagnosed with Parkinson's disease.

I have never been treated with CD/LD.

See 2 more

Exclusion Criteria

I have not taken pramipexole or aprepitant in the last 3 months.

My kidneys are not working well (Creatinine Clearance: < 60 mL/min).

I am currently taking medications like Pramipexole, Warfarin, or hormonal contraceptives.

See 8 more

Treatment Details

Interventions

Aprepitant (Neurokinin-1 Receptor Antagonist)
Pramipexole ER (Dopamine Agonist)

Trial OverviewThe trial is testing CTC-413 which includes pramipexole ER combined with aprepitant for safety and initial effectiveness in treating parkinsonian disorders. It's a Phase 2 study where patients agree to follow all procedures required by the research team.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: CTC-413Experimental Treatment1 Intervention

Pramipexole with/with out aprepitant orally once daily